Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Crit Rev Biochem Mol Biol. 2018 Jun;53(3):279–310. doi: 10.1080/10409238.2018.1458070

Figure 1. The mevalonate-isoprenoid-cholesterol pathway and pharmacological agents that inhibit the synthesis of key intermediates.

Figure 1.

HMGCS: 3-hydroxy-3-methylglutaryl-CoA synthase; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase; FPPS: Farnesyl pyrophosphate synthase; N-BPs: Nitrogen-containing bisphosphonates; SQS: Squalene synthase; GGPPS: Geranylgeranyl pyrophosphate synthase; FTase: Farnesyltransferase; GGTase-I/II: Geranylgeranyltransferase-I/II; FTIs: Farnesyltransferase inhibitors; GGTIs: Geranylgeranyltransferase inhibitors. A color version of the figure is available online.